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The aim of this study was to establish the radiosensitising properties of gemcitabine in a pair of related bladder tumour cell lines with
differential radiosensitivity. The radioresistant bladder tumour cell line MGH-U1 and its radiosensitive mutant clone, S40b (both p53
mutant), had SF2 values (surviving fraction at 2Gy) of 0.98 and 0.64, respectively (Po0.001). Colony-forming assays showed that at
0.01mM gemcitabine radiosensitisation occurred only in the S40b cell line (dose-modifying factor (DMF)¼1.4). At 0.3mM (killing 50%
of cells), both cell lines were radiosensitised; DMF¼2.25 and 1.2 for MGH-U1 and S40b, respectively. These data suggest that
gemcitabine is an effective radiosensitiser in bladder cancer cell lines, with greater sensitisation in the radioresistant parental line–a
feature that should be useful in a clinical setting.
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The incidence of bladder cancer is estimated at 13000 cases per
annum in the UK (Office of Population Censuses and Surveys,
1995). Of these, approximately 20% are invasive transitional cell
carcinomas (TCC) (T2þ). Radical radiotherapy as a treatment for
invasive TCC of the bladder is well established. The overall 5-year
survival rates are 24–29% (Blandy et al, 1980; Fossa et al, 1993), a
figure lower than in some surgical series (Skinner et al, 1991).
However, in some reported series, radiotherapy has overall 5-year
survival figures similar to radical cystectomy (Jenkins et al, 1988).
Although both treatments have comparable morbidity and
mortality, there is one fundamental difference: with radiotherapy,
the patient retains a functioning natural bladder and males will
usually retain erectile function. Thus, radiotherapy has greater
potential to help retain better quality of life after treatment.
The lower survival following radiotherapy in some series vs
others can be attributed to the differing degrees of heterogeneity
among the tumours or to the inadequate delivery of radiation.
Chemotherapeutic agents that have the ability to radiosensitise
tumours may result in more promising outcomes for TCC treated
with radiotherapy.
The pyrimidine analogue gemcitabine has been studied as a
radiosensitiser in a variety of preclinical models including colon,
pancreas, head and neck, lung and mammary tumour cells
(Shewach et al, 1994; Lawrence et al, 1996; Mason et al, 1999;
Pacini et al, 1999; Fields et al, 2000; Robinson and Shewach, 2001).
These studies showed that chemoradiation using gemcitabine
produced radiation dose-modifying factors (DMF) of between 1.1
and 3 using various combinations of drug and radiation. The
radiosensitising effects were dependent on dose, time of admin-
istration and tumour cell type. Effective radiosensitising doses
could be as little as 0.1mM (a noncytotoxic dose), even using short
incubation times (4h), but the radiosensitising effects tended to
plateau at higher cytotoxic drug levels. Furthermore, the highest
value of DMF was seen when gemcitabine was administered at least
24h prior to irradiation.
There have been studies using TCC cell lines that have shown
conflicting results. Fechner et al (2003) studied four different TCC
cell lines (RT112, RT4, T24 and SUP) with differing p53 status and
found that the addition of gemcitabine resulted in no radio-
sensitising effect. Another study (Pauwels et al, 2003) investigated
a number of tumour cell types including an epidermioid bladder
cancer cell line (ECV304) and found significant radiosensitising
effects caused by gemcitabine. They found dose enhancement
factors of 1.39–3.05 depending on the concentration used. It is
likely that these differences are due to the experimental technique.
Neither study utilised the standard colony-forming assay, which is
the accepted principal technique providing data with direct
implications for radiotherapy efficacy regarding tumour control.
Further work with TCC cell lines is therefore essential if this agent
is to be used clinically.
In an attempt to understand how gemcitabine radiosensitises, its
effects have been studied in relation to a number of factors including
dATP reduction, alteration of DNA repair, cell cycle perturbations,
deoxycytidine kinase levels and apoptosis (Shewach et al, 1994;
Joschko et al, 1997; Gregoire et al, 1998, 2002; Milas et al, 1999;
Ostruszka and Shewach, 2000; Lawrence et al, 2001; Van Putten et al,
2001). Chen et al (2000) postulated that the radiosensitising effects
of gemcitabine might be related to p53 status. However, they
concluded in their study on RKO-E6 and RKO-P colon cancer cell
lines, which differed in p53 status, that it was not the single most
important factor. Later, Robinson and Shewach (2001) studied Received 17 October 2003; accepted 8 November 2003
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srelated MCF-7 breast cancer cell lines with different p53 status and
found no difference in radioenhancement by dFdC.
The study of related cell lines and the differential effects of
treatments upon them may increase our understanding regarding
the molecular mechanisms that increase or decrease survival.
There are few such TCC models available. The MGH-U1 cell line
can be regarded as a standard TCC cell line that is known to be
relatively radioresistant (McMillan and Holmes, 1991). Utilising
mutagenic and limiting dilution techniques, the S40b cell line was
isolated from MGH-U1. This mutant clone has previously been
shown to be significantly more radiosensitive than the parent
MGH-U1 cell line and together they provide a valuable study
model. Therefore, the aims of our study were to investigate the
radiosensitising effects of gemcitabine in these two related TCC
cell lines in relation to both p53 and cell cycle perturbations.
METHODS
Cell lines
The TCC cell lines (MGH-U1 and its subclone S40b) and a human
fibroblast cell line (HF19) were grown as monolayers in HAMS F12
culture medium (containing 1mML -glutamine, GibcoBRL) supple-
mented with 10% foetal calf serum, 100IUml
 1 penicillin and
0.1mgml
 1 streptomycin (GibcoBRL). All cultures were kept at 371C
in a mixture of 3% O2,5 %C O 2 and 92% N2. They were constantly
checked for Mycoplasma spp infection, which remained absent. Cells
were subcultured regularly to ensure exponential growth.
Gemcitabine dose–response
The micro-tetrazolium assay (MTT) [3-(4,5-dimethylthiazol-2yl)-
2,5-diphenyl-tetrazoliumbromide], optimised for MGH-U1 and
S40b, was used to assess the gemciatbine dose–response curve.
Exponentially growing cells (200 MGH-U1 cells and 400 S40b cells)
in 100ml media were plated in 96-well plates (Helena BioSciences,
Sunderland, UK). Cells were incubated for 24h to allow adherence
after which they were treated for 4h with varying doses of
gemcitabine (0–10mM) (Gemzar, Eli Lilly & Co., Basingstoke, UK).
A stock solution of gemcitabine (1000mM in PBS) was diluted to
appropriate concentrations in Hams F12 media containing 1mML -
glutamine (GibcoBRL, Paisley, UK) and supplemented with 10%
foetal calf serum. After exposure, cells were washed with
phosphate-buffered saline (PBS) and fresh medium was added.
Following incubation for a further 7 days, 50ml of 1mgml
 1 3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyl-tetrazoliumbromide in PBS was
added to each well. Cells were incubated for 5h at 371C, then the
medium was aspirated and the resultant formazan crystals were
resuspended in 200ml of DMSO. Plates were read at 540 and 690nm
on a Multiskan platereader (Flow Ltd, Ayrshire, UK). Growth
inhibition was calculated using an Excel MTT program (written by
Dr Tim Ward, Drug Development and Imaging Group, Paterson
Institute for Cancer Research, UK), which calculates the growth of
treated cells as a fraction of that for the untreated control cells. The
data were then plotted and analysed using unweighted nonlinear
least-squares regression to identify significant differences between
the two dose–response curves. The doses of gemcitabine resulting
in 10–20% (IC10–20) and 50% (IC50) cell kill were derived from the
curves.
Radiation alone and in combination with gemcitabine
To assess cell kill after radiation alone and in combination with
gemcitabine, subconfluent cell monolayers of MGH-U1 and S40b
were trypsinised and diluted to form a single cell suspension of
1 10
5 cellsml
 1, which was then gamma-irradiated on ice
(1Gymin
 1). After irradiation, the cells were diluted, so that the
appropriate number of cells were seeded into 60mm culture dishes
in order to give at least 50 colonies. At 10 days after irradiation,
colonies comprising at least 50 cells were stained with gentian
violet and then counted.
For chemoradiation experiments, cells were incubated for 4h
with the IC10–20 and IC50 concentrations of gemcitabine 12h prior
to irradiation. Experiments were repeated in order to provide at
least three sets of independent data, which were fitted using the
linear quadratic model.
The number of colonies surviving 2Gy of irradiation (SF2) was
taken as a measure of radiosensitivity. Enhancement of the
radiation response by gemcitabine (synergy) was defined as any
effect on cell kill that was greater than would be expected from
addition of the effects of the two agents alone. Analysis of variance
and the F-test were used to compare the dose–response curves,
which were fitted to the linear quadratic model, for irradiation
alone and irradiation and gemcitabine combined.
Cell cycle changes with single and combination treatment
MGH-U1 and S40b cells were plated into tissue culture flasks and
given 2Gy irradiation, IC50 gemcitabine, both IC50 Gemcitabine
and 2Gy, or no treatment. At various time points after treatment
(0–48h) flasks were trypsinised and cells were collected by
centrifugation, resuspended in 200ml PBS and fixed in 2ml ice cold
70% ethanol at 41C for at least 30min. The cells were collected by
centrifugation and resuspended in a mixture of PBS (400ml),
1mgml
 1 RNase (100ml) and 400mgml
 1 of propidium iodide
(50mg) before incubating at 371C for 30min. Cell cycle analysis
was carried out using a Becton Dickinson FACScan flow cytometer
at 488nm. For each treatment, the changes were calculated in the
percentage of cells in each part of the cell cycle (G0/1, S and G2/M)
compared to untreated controls.
p53 functional analysis
The cell lines MGH-U1 and S40b along with HF19 (positive control)
were analysed for the presence of p53. Approximately 2 10
5 cells
were plated and grown to ensure exponential growth. Cultures were
then washed twice with PBS (5ml) and then scraped in PBS (5ml)
and centrifuged (390g) for 5min. Pellets were resuspended in 1ml of
PBS and transferred to Eppendorf tubes before centrifuging (11600g)
for 2min. The cells were resuspended in 100ml of paraformaldehyde
(4%) and left at room temperature for 30min then washed twice in
PBS by centrifugation before resuspending in 100ml of permeabilisa-
tion buffer (Saponin) containing p53 mouse monoclonal antibody
(1:50) (D0-7, Novocastra, UK) and incubated for 60min at 371C. The
cells were then washed twice in permeabilisation buffer before adding
100ml of buffer containing fluorescent-tagged rabbit antimouse
antibody (1:40) (DAKO Ely, UK) and left to stand at room
temperature for 45min. After washing twice in PBS, by centrifugation
cells were resuspended in a mixture of PBS (400ml), 1mgml
 1 RNase
(100ml) and 400mgml
 1 of propidium iodide (50mg) before
incubating for 30min at 371C. As a negative control the above
process was repeated, but omitting the addition of the p53 antibody.
Cell suspensions were analysed by flow cytometry (Becton Dickinson
FACScan) at 488nm. The relative fluorescence was calculated by
normalising against negative controls. Experiments were carried out
on two independent occassions. The Student’s t-test was used to
detect any significant difference between the two cell lines.
The functional status of p53 was established by the assessment
of cell cycle arrest after 2Gy (see above).
RESULTS
Gemcitabine dose–response
The dose–response curves for MGH-U1 and S40b when treated with
gemcitabine are shown in Figure 1. There was no statistical
significance between the response of the two cell lines. The IC10–20
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swas approximately 0.01mM for each cell line, while the IC50 was 0.25
and 0.35mM for S40b and MGH-U1, respectively. The doses used for
further experiments were 0.01mM (IC10-20)a n d0 . 3mM (average IC50).
Radiation dose–response
Using the colony–forming assay and fitting the data to the linear
quadratic model, a significant difference was observed between the
radiosensitivities of both cell lines. The surviving fraction at 2Gy
(SF2) was 0.9870.09 and 0.6470.01 for MGH-U1 and S40b,
respectively (Po0.001) (Figure 2).
Radiation with gemcitabine
When gemcitabine was given for a 4-h incubation commencing
12h prior to irradiation, 0.01mM (IC10–20) radiosensitisation
occurred in the radiosensitive S40b cell line (DMF¼1.4;
Po0.01), while in the MGH-U1 cell line, there was no significant
change from irradiation alone (DMF¼1.1) (Figure 3A, B). At
0.3mM (IC50) both cell lines were radiosensitised, but the effect was
considerably greater in the radioresistant MGH-U1 cell line
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Figure 1 Dose–response curves for MGH-U1 (squares) and S40b
(circles and dashed line) cell lines treated with dFdC. Data were obtained
from three repeat MTT experiments.
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Figure 2 Clonogenic radiation survival curves for MGH-U1 (squares)
and S40b (circles). Data from three independent experiments were
averaged and fitted to the linear quadratic model. SF2 for MGH-
U1¼0.9870.09 and S40b¼0.6470.01.
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Figure 3 (A–D) Clonogenic survival curves for cells given irradiation
alone (squares) and gemcitabine (4-h incubation) 12h prior to irradiation
(circles); 0.01mM gemcitabine in S40b (A) and MGH-U1 (B); 0.3mM
gemcitabine in S40b (C) and MGH-U1 (D). Dose modification factors
(DMF) were calculated at IC50 and were 1.4 (Po0.01), 1.1 (not significant),
1.2 (Po0.01) and 2.25 (Po0.001) for A, B, C and D, respectively.
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s(DMF¼2.25; Po0.001) than in the radiosensitive S40b cell line
(DMF¼1.2; Po0.01) (Figure 3C, D).
Cell cycle changes with single and combination treatment
The greatest difference in the radiosensitising effect of gemcitabine
between the cell lines was seen at 0.3mM rather than at 0.01mM, and
the former higher dose level was therefore used to study cell cycle
effects.
In both cell lines after irradiation, no G1/S block occurred
and cells accumulated in G2/M (Table 1A, B). A G2/M
block was noted: this peaked at 8h in both S40b and
MGH-U1 and persisted for 12 and 8h for S40b and MGH-U1,
respectively.
Table 1 Cell cycle changes after treatment with gemcitabine (0.3mM) (4-h incubation) and/or irradiation (2Gy) in MGH-U1 (A) and S40b (B) cell lines
G1 S G2/M
Treatment Time (h) % Change 7 s.e. % Change 7 s.e. % Change 7 s.e.
(A) MGH-U1
Irradiation alone
0  2 1.5 2 1.3 0 0.5
4  14 2.8 3 1.1 11 1.9
8  11 9.5  13 5.0 24 4.5
12 8 1.9  15 0.8 7 1.7
16 1 2.3 0 2.8  2 0.6
24 1 3.1  6 2.6 5 1.2
36  2 0.8  2 2.5 3 2.9
48 0 2.3  2 2.2 2 3.4
Gemcitabine alone
0  2 1.5 2 1.3 0 0.5
4 19 1.4  5 1.3  14 0.1
8 9 11.2  3 3.4  8 7.9
12 24 1.4  9 2.1  15 0.7
16 24 0.4  10 1.5  14 1.6
24 21 1.4  3 1.2  18 0.3
36 18 0.6  3 1.2  15 0.6
48 20 2.4  6 2.4  14 1.9
Gemcitabine/irradiation
0 22 3.4  6 3.3  16 0.4
4 22 3.5  8 2.7  14 1.4
8 18 11.7  9 3.0  9 8.9
12 21 1.3  4 1.5  18 0.3
16 16 1.8  1 2.2  15 0.4
24 17 3.7  3 4.0  14 0.3
36 15 1.0 0 1.3  14 1.9
48 16 1.7 0 3.6  15 2.5
(B) S40b
Irradiation alone
0  1 5.7 3 3.1  1 4.6
4  9 2.6 7 1.8 2 1.9
8  27 5.4 1 3.3 26 2.2
12  13 3.8  6 1.3 19 3.3
16  1 5.5  7 5.9 9 2.8
24 1 4.1 1 1.9  3 2.7
36 1 4.4  4 3.2 3 1.3
48  4 3.7 1 3.2 3 0.5
Gemcitabine alone
0  1 5.7 3 3.1  1 4.6
4 18 7.5 2 1.0  20 7.9
8 10 2.1 3 1.9  13 0.2
12 12 3.5  1 2.1  11 2.3
16 19 1.5  7 2.2  12 1.5
24  21 10.9 34 9.4  12 2.3
36  26 4.0 36 6.8  10 3.1
48  26 6.2 31 1.6  4 7.8
Gemcitabine/irradiation
0 14 3.2  3 1.4  11 2.4
4 16 2.9  5 1.5  12 1.5
8 18 1.9  5 1.6  14 0.2
12  14 7.9 27 9.1  13 2.0
16  39 8.6 46 5.3  7 3.7
24  13 2.7 19 5.9  6 3.2
36  15 4.8 21 5.8  5 2.6
48  13 5.9 16 8.9  2 3.4
In combination experiments, gemcitabine was given 12h prior to irradiation. The figures represent the percentage change in the proportion of cells in each part of the cell cycle in
comparison to untreated controls. Negative figures represent a reduction in the proportion of cells. Data are obtained from three independent experiments.
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sWhen treated with gemcitabine alone (0.3mM; 4-h incubation),
both cell lines exhibited a G1/S block (Table 1A, B). In S40b, the
peak occurred at 4h and the duration was approximately 12h after
which there was an accumulation of cells in the Sphase. In
contrast, MGH-U1 showed a peak at 12h and the G1/S block was
still present at 48h.
With both irradiation and gemcitabine (0.3mM; 4-h incubation,
12h preirradiation), the G1/S block was observed again (Table 1A,
B). The data suggest that the changes observed are similar to those
from gemcitabine alone. While studying the duration of the blocks,
it should be noted that gemcitabine was given 12h prior to the first
data point in the combination experiments thus showing that the
G1/S block in S40b lasted 20h, while in MGH-U1 it was still
present 60h post gemcitabine. It was observed that in S40b, there
was a subsequent accumulation of cells in the Sphase; this did not
occur in more radiosensitised MGH-U1 cells.
p53 functional analysis
p53 expression was 90 (s.e.74) and 182 (s.e.724) fluorescence
units for MGH-U1 and S40b, respectively (P¼0.12). Cell cycle
analysis after 2Gy in both cell lines showed no G1/S block,
suggesting that the p53 was mutant in both cell lines (Table 1A, B).
DISCUSSION
The ability to improve organ-preserving treatments for bladder
cancer hinges on adequate preclinical evaluation. This is in order
to predict possible clinical responses, suggest scheduling and also
to report the possible mechanisms of action that may aid future
treatment selection programmes. The aim of the current study was
to identify the radiosensitising effect of gemcitabine on TCC cell
lines using the conventional colony-forming assay. We chose two
related cell lines with differing radiosensitivities and studied the
effects in relation to p53 status and cell cycle perturbations in
order that if any difference was elucidated, then it could lead to
possible mechanisms of action, which to date are not fully
explained for this agent.
The present study shows that low doses of gemcitabine
radiosensitise only the S40b cell line while higher doses radio-
sensitise S40b and MGH-U1. The results suggest that gemcitabine’s
mechanism of action may depend on the concentration of the drug
itself and the presence or absence of certain cellular stress response
signals. We previously studied the radiation stress response
elements of these two cell lines (Kassem et al, 2002) using the
Atlas human stress cDNA arrayt. Of 234 genes blotted on the
array, 14 (6%) showed a difference in S40b relative to MGH-U1. In
all, 12 genes were down regulated in S40b (HSP90, HSP27, HSP47,
heat shock transcription factor 1, NNMT, vimentin, calreticulin
precursor, transformation sensitive protein, CDKN1A, GADD153,
FLAP endonuclease 1 and NADH-cytochrome b5 reductase) and
two genes were upregulated (MAPKK2 and MAPKK5). Whether
any of these could be responsible for the differences in response
observed in this study is debatable and certainly requires further
evaluation.
Previous studies on bladder tumour cell lines have produced
conflicting results regarding the ability of gemcitabine to radio-
sensitise (Fechner et al, 2003; Pauwels et al, 2003). Fechner et al
studied RT112 (p53 wild type), RT4 (p53 wild type), T24 (p53
mutant) and SUP (p53 mutant) cell lines and found no radio-
sensitising effect despite gemcitabine (10–500nM) incubation
times of 24h. In that study, the MTT assay was used, which can
provide results for radiation growth delay that are often
comparable to those obtained from the colony-forming assay,
but it does give more variable and potentially inaccurate results if
the assay is not optimised. Furthermore, the assay is affected by
the radiation dose level, the concentration of MTT and the
duration of the MTT incubation (Price and McMillan, 1990;
Slavotinek et al, 1994; Banasiak et al, 1999). Also, it is known that
for survival to be accurately assessed after radiation exposure, the
cell population should undergo at least five to six doublings (Steel,
1997). In Fechner et al’s study, cells were incubated for only 3 days
after treatment during which time they would likely not have had
time to exhibit the full effect of radiation. This may have resulted
in an underestimate of cell kill and any radiosensitising effect.
Pauwels et al (2003) studied various cell lines including the
ECV304 bladder tumour cell line. In contrast to Fechner et al’s
study, they showed that a 24-h incubation with gemcitabine (1–
6n M) radiosensitised the bladder tumour cell line with enhance-
ment factors of up to 3.05. They utilised the SRB assay, which again
has been shown to provide results comparable to those obtained
from the colony-forming assay (Banasiak et al, 1999). Unlike
Fechner, they optimised the assay for each cell line used and also
allowed treated cells to grow for 8 days, thereby allowing the full
effect of radiation treatment to be expressed.
The data reported indicate that two related bladder cancer cell
lines with different radiosensitivities and similar p53 status are
radiosensitised to different extents, in relation to each other, by
pretreatment with gemcitabine. This suggests that p53 status is not
a dominant factor in the radiosensitising effect of gemcitabine and
this is supported by previous reports by Robinson and Shewach
(2001) using MCF-7 and MCF-7/Adr breast cancer cell lines and
Chen et al (2000) using RKO-P and RKO-E6 colon cancer cell lines.
The p53 protein is a tumour suppressor gene involved in the
regulation of the cell cycle largely around the G1/S checkpoint.
Although p53 status has been shown to be unrelated to
gemcitabine radiosensitisation, the data do suggest that other
factors around the G1/S checkpoint may be important in the
radiosensitising effect of dFdC. Previous studies have highlighted
the importance of S-phase accumulation as an important factor in
the radiosensitising effect of gemcitabine (Ostruszka and Shewach,
2000). However, our results show that the more radiosensitised cell
line (MGH-U1) fails to produce S-phase accumulation. Chen et al
(2000) showed that p53 wild-type RKO cells were radiosensitised
and showed S-phase accumulation, whereas p53 null RKO cells,
although showing radiosensitisation, did not accumulate in
Sphase. The current data show that the p53 mutant MGH-U1
cells did not show S-phase accumulation, but its related p53
mutant S40b did, despite both being radiosensitised by gemcita-
bine. These contradicting data would suggest that S-phase
accumulation is unlikely to be a major mechanism of radio-
sensitisation by gemcitabine.
The G1 arrest exhibited at 0.3mM of gemcitabine in combination
with irradiation in this study was persistant in MGH-U1 for the
duration investigated but in S40b lasted approximately 20h. The
corresponding radiosensitising effect was greater in MGH-U1 than
in S40b. The stasis of cells in G1 may result in reduced DNA
replication and possibly repair, which may allow the effects of
radiation to be greater, as in MGH-U1. However, when cells begin
to recycle, it allows them to reinitiate DNA synthesis and repair
thereby giving stressed cells a greater ability to recover. This might
explain the lower degree of radiosensitisation observed in S40b.
The cell cycle effects of gemcitabine were studied extensively by
Cappella et al (2001). They concluded that the effect of gemcitabine
on the cell cycle occurs in two phases. Firstly, a cytostatic phase
that results in G1 arrest and secondly, a phase of recycling and
DNA synthesis in incompletely recovered cells. This second phase
holds the fate of cells and is balanced by DNA synthesis and
apoptosis. Our results would support these findings. However,
Cappella and co-workers also showed that a second treatment by
gemcitabine or cisplatinum potentiated cell kill, if it was given
when cells were in the second phase. The model used in our study
would not predict this finding. Although we only studied cell cycle
changes at the IC50 dose, we can postulate that it is likely that,
regarding radiosensitisation with gemcitabine, the presence and
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sduration of the cytostatic phase (G1 arrest) and the ability of the
cells to replicate or repair DNA is of importance. Furthermore,
workers (Merlin et al, 1998; Cappella et al, 2001) have suggested
that p53 is involved only in the cytotoxic rather than the cytostatic
phase, which would support our findings that p53 is unimportant
in the radiosensitising effect of gemcitabine.
An attractive property of the radiosensitising effect of gemci-
tabine is that it occurs at noncytotoxic doses. This study shows
that at noncytotoxic doses of gemcitabine, only one of the bladder
tumour cell lines (S40b) is significantly radiosensitised, whereas
both cell lines were radiosensitised when cytotoxic doses were
administered. Phase I and II clinical studies of chemoradiation
with gemcitabine have reported maximum recommended doses of
300–400mgm
 2 in a once-weekly schedule (Pattaranutaporn et al,
2001; Wolff et al, 2001). These doses are low in comparison to the
standard dose of 1000–1200mg/m
2 (Stadler et al, 1997; von der
Maase et al, 2000) and are likely to be relatively noncytotoxic. Our
results suggest that at such low doses radiosensitisation may be
slight and much higher doses may be required, although this
would be at the expense of normal tissue toxicity. A method of
bypassing this problem and achieving possibly better results would
be to adopt a trial design in which gemcitabine is given in its
standard dose of 1000mgm
 2 and for the radiation dose to be
initially reduced prior to escalation. Chen et al (2000) also
postulated this and they are currently undertaking such trials for
pancreatic cancer.
In conclusion, the fluorinated pyrimidine gemcitabine has the
potential to improve organ-preserving cancer treatments. It has
differential radiosensitising properties in bladder cancer cell lines
in vitro and while G1 arrest is likely to be important, its effects are
certainly unrelated to p53 status. It is likely that there are several
factors involved in radiosensitising properties of gemcitabine. A
greater understanding of its mechanism of action may aid patient
selection. Further work should be directed at investigating the
differences in cellular response, between related tumour cells, to
this combination treatment.
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